Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Center, Double-Blind, Placebo Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ABP-700 after a Single Ascending Bolus Dose

Next Previous
X
Search
Trial Profile

A Phase 1, Single-Center, Double-Blind, Placebo Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ABP-700 after a Single Ascending Bolus Dose

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclopropyl-methoxycarbonylmetomidate (Primary)
  • Indications Anaesthesia
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Annovation BioPharma

    • Most Recent Events

    • 01 Jan 2021 Results (n=350) from NTR4545, NTR4735, NTR5173, NTR5231, and NTR5442 modeling the effect of excitation on depth of anesthesia in ABP-700, published in the Anesthesiology
    • 01 Jul 2017 Results published in the Anesthesiology
    • 17 Feb 2016 According to The Medicines Company media release, the company presented the first clinical results addressing the safety and tolerability of ABP-700 at the ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacologists annual meetings.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top